Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai biologics communication registry (TBCR) study

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 339-345

  Kojima, Toshihisa ^a   Kaneko, Atsushi ^b   Hirano, Yuji ^c   Ishikawa, Hisato ^d   Miyake, Hiroyuki ^e   Oguchi, Takeshi ^f   Takagi, Hideki ^g   Yabe, Yuichiro ^h   Kato, Takefumi ⁱ   Ito, Takayasu ^j   Terabe, Kenya ^k   Fukaya, Naoki ^l   Kanayama, Yasuhide ^g   Shioura, Tomone ^m   Funahashi, Koji ^a   Hayashi, Masatoshi ^a   Kato, Daizo ^a   Matsubara, Hiroyuki ^a   Fujibayashi, Takayoshi ⁿ   Kojima, Masayo ^o   Ishiguro, Naoki ^a,p   more..

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d NAGANO RED CROSS HOSPITAL   (Japan)

^e Ichinomiya Municipal Hospital   (Japan)

^f ANJO KOSEI HOSPITAL   (Japan)

^g Nagoya Kyoritsu Hospital   (Japan)

^h TOKYO KOSEI NENKIN HOSPITAL   (Japan)

ⁱ Kato Orthopedic Clinic   (Japan)

^j Ito Orthopedic Clinic   (Japan)

^k Fukuroi Municipal Hospital   (Japan)

^l Kariya Toyota General Hospital   (Japan)

^m Shizuoka Kosei Hospital   (Japan)

ⁿ Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^o NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^p NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Age; Biologics; Methotrexate; Registry; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BIOLOGICAL THERAPY; CLINICAL PROTOCOL; DISEASE COURSE; DISEASE DURATION; DISEASE REGISTRY; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; JAPAN; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TREATMENT OUTCOME;

EID: 84865388690     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0518-4     Document Type: Article

References (13)

1. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
2. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898-906.
3. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659-62.
4. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol. 2006;33:2398-408. (Pubitemid 46067817)
5. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300.
6. Hyrich KL, Watson KD, Isenberg DA, Symmons DP. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford). 2008;47:1441-3.
7. Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: Results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495-9.
8. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
9. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
10. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54: 628-34. (Pubitemid 43228641)
11. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16:75-6.
12. Matsui T, Kuga Y, Kaneko A, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221-6. (Pubitemid 47309741)
13. Sakai R, Komano Y, Tanaka M, et al. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Mod Rheumatol. 2011.